Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRENASDAQ:COLLNASDAQ:IMABNASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.80+4.0%$1.74$1.41▼$5.01$9.95M1.1926,256 shs31,321 shsCOLLCollegium Pharmaceutical$31.47+1.8%$29.30$23.23▼$42.29$1.01B0.64367,548 shs142,273 shsIMABI-Mab$2.22+6.2%$1.67$0.60▼$3.08$181.29M1.4391,750 shs379,557 shsSTOKStoke Therapeutics$12.05+3.1%$10.47$5.35▼$16.15$657.93M1.14671,046 shs325,128 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-1.14%+2.37%-1.14%+5.58%-55.41%COLLCollegium Pharmaceutical+1.75%+4.50%+2.32%+21.61%-3.98%IMABI-Mab-6.28%-13.64%-14.69%+204.66%+30.63%STOKStoke Therapeutics+1.78%+3.00%+4.94%+98.14%-10.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPREAprea Therapeutics2.5234 of 5 stars3.54.00.00.00.00.81.3COLLCollegium Pharmaceutical4.2589 of 5 stars3.41.00.03.03.10.82.5IMABI-Mab2.8904 of 5 stars3.73.00.00.02.21.70.6STOKStoke Therapeutics4.0055 of 5 stars3.60.00.04.82.30.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 3.00Buy$15.50761.11% UpsideCOLLCollegium Pharmaceutical 2.75Moderate Buy$43.7539.02% UpsideIMABI-Mab 3.33Buy$6.00170.27% UpsideSTOKStoke Therapeutics 3.29Buy$23.2092.53% UpsideCurrent Analyst Ratings BreakdownLatest STOK, APRE, IMAB, and COLL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.006/27/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.006/26/2025APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.005/14/2025STOKStoke TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$47.00 ➝ $35.005/9/2025COLLCollegium PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.004/9/2025COLLCollegium PharmaceuticalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.004/9/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$1.50M6.64N/AN/A$3.55 per share0.51COLLCollegium Pharmaceutical$631.45M1.60$12.79 per share2.46$7.10 per share4.43IMABI-Mab$3.89M46.60N/AN/A$2.47 per share0.90STOKStoke Therapeutics$36.56M18.00N/AN/A$4.32 per share2.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.96M-$2.37N/AN/AN/A-1,095.02%-68.39%-55.74%8/11/2025 (Estimated)COLLCollegium Pharmaceutical$69.19M$1.2225.805.23N/A6.61%99.08%15.14%8/6/2025 (Estimated)IMABI-Mab-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)STOKStoke Therapeutics-$88.98M$0.7915.25N/AN/A26.33%19.08%15.72%8/5/2025 (Estimated)Latest STOK, APRE, IMAB, and COLL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025STOKStoke Therapeutics-$0.0905N/AN/AN/A$31.51 millionN/A5/14/2025Q1 2025APREAprea Therapeutics-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 million5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ACOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A5.905.90COLLCollegium Pharmaceutical3.301.081.01IMABI-MabN/A22.3522.35STOKStoke TherapeuticsN/A8.418.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%COLLCollegium PharmaceuticalN/AIMABI-Mab38.38%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics13.63%COLLCollegium Pharmaceutical2.51%IMABI-Mab22.10%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics75.53 million4.78 millionNo DataCOLLCollegium Pharmaceutical21032.13 million31.33 millionOptionableIMABI-Mab38081.66 million63.61 millionOptionableSTOKStoke Therapeutics10054.60 million49.41 millionOptionableSTOK, APRE, IMAB, and COLL HeadlinesRecent News About These CompaniesStoke City move early for 'lethal' rising Manchester City star in second signing of the dayJuly 7 at 4:49 AM | msn.comNew Hanford waste incinerator could keep patients warm at Royal StokeJuly 7 at 4:49 AM | msn.comStoke sign Talovierov and Man City's MubamaJuly 7 at 4:49 AM | msn.comZebra crossings to be installed outside TWO schools on same Stoke-on-Trent roadJuly 5 at 11:14 PM | msn.comStoke-on-Trent-based Prohire Limited falls into administrationJuly 5 at 11:14 PM | bbc.co.ukMaksym Talovierov makes 'cold nights' promise with brilliant Stoke City statementJuly 5 at 11:14 PM | msn.comDONE DEAL: Stoke snap up Man City striker MubamaJuly 5 at 11:14 PM | tribalfootball.comTFive Guys to open first Stoke-on-Trent restaurantJuly 5 at 11:14 PM | msn.comMubama set for Stoke loan switchJuly 5 at 11:14 PM | sports.yahoo.comPorch pirates target Stoke-on-Trent as parcels swiped from doorstepsJuly 3, 2025 | uk.news.yahoo.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives $23.20 Average Target Price from BrokeragesJuly 3, 2025 | americanbankingnews.comStoke City on brink of agreement for Plymouth Argyle record signingJuly 2, 2025 | msn.comStockley named Stoke's new academy managerJuly 2, 2025 | msn.comStoke Therapeutics' (STOK) "Buy" Rating Reaffirmed at Needham & Company LLCJuly 1, 2025 | marketbeat.comMichelin’s Stoke-on-Trent plant set to lower CO2 emissions with tyre reprocessing siteJuly 1, 2025 | thebusinessdesk.comTStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Buy" from AnalystsJune 30, 2025 | marketbeat.comSTOK Stoke Therapeutics, Inc. - Seeking AlphaJune 29, 2025 | seekingalpha.comAnalysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Legend Biotech (LEGN)June 28, 2025 | theglobeandmail.comStoke-on-Trent bungalow could be turned into children's homeJune 28, 2025 | msn.comStoke City confirm new coach appointment as pre-season startsJune 27, 2025 | msn.comTraditional Stoke-on-Trent pub reopens for the first time since CovidJune 27, 2025 | stokesentinel.co.ukSNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTOK, APRE, IMAB, and COLL Company DescriptionsAprea Therapeutics NASDAQ:APRE$1.80 +0.07 (+4.05%) As of 02:36 PM EasternAprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Collegium Pharmaceutical NASDAQ:COLL$31.47 +0.57 (+1.84%) As of 02:56 PM EasternCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.I-Mab NASDAQ:IMAB$2.22 +0.13 (+6.22%) As of 02:51 PM EasternI-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.Stoke Therapeutics NASDAQ:STOK$12.05 +0.36 (+3.08%) As of 02:51 PM EasternStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
